We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / OTHER PHARMACEUTICALS
OTHER THERAPEUTIC AREAS. Film coated tablets for oral uses

OTHER PHARMACEUTICALS

Lesvi also offers a portfolio for a range of other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
12
Product Indication Dosage form Strength
Azithromycin Macrolide antibacterial Film-coated tablets 500 mg
Azithromycin Macrolide antibacterial Powder for oral suspension 200 mg/5 ml
Calcium Dobesilate [S] Non proliferative diabetic retinopathy Hard capsules 500 mg
Ciprofloxacin otic Otitis Ear drops, solution (unit dose) 1 mg
Clopidogrel Atherothrombosis Film-coated tablets 75 mg
Desloratadine Allergy Film-coated tablets 5 mg
Dexketoprofen Analgesic Film-coated tablets 12.5 and 25 mg
Enalapril Hypertension Tablets 5 and 20 mg
Enalapril + HCTZ Hypertension Tablets 20/12.5 mg
Fluconazol Antifungal Hard capsules 50, 100, 150 and 200 mg
Fluconazol Antifungal Powder for oral suspension 200 mg/5ml and 50 mg/5ml
Imidapril [S] Hypertension Tablets 5, 10 and 20 mg
Irbesartan Hypertension Film-coated tablets 75, 150 and 300 mg
Irbesartan + HCTZ Hypertension Film-coated tablets 150/12.5, 300/12.5 and 300/25 mg
Ketorolac Analgesic Film-coated tablets 10 mg
Lisinopril Hypertension Tablets 5 and 20 mg
Lisinopril + HCTZ Hypertension Tablets 20/12.5 mg
Loratadine Allergy Film-coated tablets 10 mg
Montelukast Asthma, allergy Chewable tablets 4 and 5 mg
Montelukast Asthma, allergy Film-coated tablets 10 mg
FDF PRODUCT PORTFOLIO

[S] Singular Generics

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.